Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
| CAPS Rating |
|
|---|
PGNX
VS S&P 500 (SPY)
PGNX News and Commentary
- 3 Biotech Stocks With Key FDA Summer Dates – SeekingAlpha
- Bio-Pharma Stocks To Watch For Next Week – SeekingAlpha
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2 – SeekingAlpha
- Friday's Bio Pharma Potential Catalyst Price Movers – SeekingAlpha
- Progenics Pharma: Several Short Term Catalysts With Good Long Term Fundamentals – SeekingAlpha
- Dendreon Likely to Jump Higher on Strong Pipeline – Blogs @ The Motley Fool
- Salix Beats; Ups EPS Outlook - Analyst Blog – NASDAQ
- Salix Faces Regulatory Delays - Analyst Blog – NASDAQ
- Vivus Wins FDA Approval – Minyanville
How do you think PGNX will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
164
Outperform
19
Underperform
All-Star Players
27
Outperform
3
Underperform
Wall Street
6
Outperform
1
Underperform
RSS Headlines
Fool UK
